Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-08T15:59:51.220Z Has data issue: false hasContentIssue false
  • English
  • Français

PCP analogues in samples of Barcelona from 2009 to 2015

Published online by Cambridge University Press:  23 March 2020

M. Angelats ,
L. Galindo ,
M. Grifell ,
Á. Palma ,
L. Martínez ,
L. Pujol ,
M. Ventura ,
I. Fornís ,
M. Torrens  and
M. Farré
M. Angelats*
Affiliation:
Instituto de Neuropsiquiatría y Adicciones INAD, Parc de Salut Mar, Psiquiatria, Barcelona, Spain
L. Galindo
Affiliation:
Instituto de Neuropsiquiatría y Adicciones INAD, Parc de Salut Mar, Psiquiatria, Barcelona, Spain
M. Grifell
Affiliation:
Instituto de Neuropsiquiatría y Adicciones INAD, Parc de Salut Mar, Psiquiatria, Barcelona, Spain
Á. Palma
Affiliation:
Instituto de Neuropsiquiatría y Adicciones INAD, Parc de Salut Mar, Psiquiatria, Barcelona, Spain
L. Martínez
Affiliation:
Instituto de Neuropsiquiatría y Adicciones INAD, Parc de Salut Mar, Psiquiatria, Barcelona, Spain
L. Pujol
Affiliation:
Instituto de Neuropsiquiatría y Adicciones INAD, Parc de Salut Mar, Psiquiatria, Barcelona, Spain
M. Ventura
Affiliation:
Energy Control, Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain
I. Fornís
Affiliation:
Energy Control, Asociación Bienestar y Desarrollo, Energy Control, Barcelona, Spain
M. Torrens
Affiliation:
Instituto de Neuropsiquiatría y Adicciones INAD, Parc de Salut Mar, Institut Hospital del Mar d’Investigacions Mèdiques IMIM, Parc de Salut Mar, Universitat Autònoma de Barcelona, Psiquiatria, Barcelona, Spain
M. Farré
Affiliation:
Institut Hospital del Mar d’Investigacions Mèdiques IMIM, Parc de Salut Mar, Universitat Autònoma de Barcelona, Servei de Farmacologia Clínica, Hospital Universitari Germans Trias i Pujol, IGTP, Farmacología, Barcelona, Spain
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Novel psychoactive substances (NPS) use is progressively increasing year on year. The new analogues of phencyclidine are frequently sold as legal dissociative anesthetic drug with hallucinogenic and sedative effects, a legal alternative to ketamine, acting as a high affinity and selective ligand of NMDA receptor antagonists.

Objectives

To describe the presence of 3- and 4-MeO-PCP in samples delivered to Energy Control from 2009 to 2015 in Spain.

Methods

A total of 21,198 samples were analyzed from august 2009 to august 2015. Only those samples containing 4-MeO-PCP or 3-MeO-PCP were studied. They were analyzed by Energy Control, a Spanish harm reduction NGO that offers the possibility of analyzing the substances that users report. Analysis was done by gas chromatography–mass spectrometry.

Results

All the samples resulted to be the acquired drug of the consumer. Three samples were adulterated with substances as tramadol, cocaine, acetone among others.

Conclusions

Three and 4-MeO-PCP consumption is not found to be an emerging issue according to the results of our samples. Even the potential harmful effects of these dissociative drugs, our indirect indicator seems to show that consumption has not increased. A more precise monitoring would make a better approach to the real consumption and the impact of these substances in our society.

Disclosure of interest

The authors declare that they have no competing interest.

Type
EW10
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S117
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.